Aurora Cannabis stock (NASDAQ/TSX: ACB) experienced severe valuation declines over recent years due to industry-wide oversupply, slower-than-expected global recreational market legalization, heavy corporate dilution from historical stock offerings, and prolonged operational unprofitability. Although the company executed massive cost-cutting measures and shifted toward higher-margin medical cannabis to stabilize its business, historical market skepticism continues to weigh heavily on its share price.